January 2020 - September 2020 (Q3)
05/11/2020
“Our company purpose is to help create more better days for patients, using pharma-based mentality for medical cannabis production” CEO, THOMAS SKOVLUND SCHNEGELSBERG
Investing in the most ambitious Medical Cannabis Supplier
Import and wholesale of high quality finished medical cannabis products for Danish patients.
Mentioned in
Company announcements
Company Introduction
Founded in Denmark in 2017, STENOCARE sole purpose is being part of the Danish four-year Programme for medical cannabis products to patients. The company is operating in a highly regulated market under the jurisdiction and control of the Danish Medical Agency – where the products are only legally available via prescription from a physician to a patient.
STENOCARE has their headquarter in Denmark, and a wholly owned subsidiary – STENOCARE Ireland Ltd – in Ireland.
STENOCARE vision
STENOCARE vision is to provide high quality medicinal cannabis that gives patients better quality of life
STENOCARE mission
STENOCARE mission is to provide uniform medical cannabis products grown and produced in hygienic climate rooms without the use of pesticide
STENOCARE 1.0 ambitions are well implemented, and we will now commence executing our strategy for STENOCARE 2.0 to become a leading medical cannabis brand in Europe Thomas Skovlund Schnegelsberg, CEO STENOCARE
STENOCARE strategy
The STENOCARE 2.0 strategy is building assets within three categories that supplement each other and are important for the success of the company:
- Commercial assets; having medical cannabis products approved in the very strict regulatory regime in Denmark enable the company to leverage this asset in Denmark and future markets. With a multi-supplier approach for sourcing patient-ready products, this is a solid platform for the planned international expansion beyond Denmark.
- Partnership assets; with doctors and patients looking for more product choice for treatment with prescription-based medical cannabis – the company will enter into research and development partnerships to bring exclusive and innovative medical cannabis product to market that differentiate its product portfolio.
- Supply chain assets; where the company control the entire value chain and build internal expertise with its own indoor cultivation facility. Having the capability of producing high quality medical cannabis that is controlled and fully documented from seed to sales in the indoor setup that emulate pharma principles is an important asset to be successful in the premium segment that STENOCARE is serving in their markets. This will enable it to supply high quality products that meet the requirements of patients, medicines agencies and the pharma industry
These three categories leverage the proven results from the STENOCARE 1.0 strategy, that made the company a first-mover in the Danish medical cannabis industry by securing regulatory approvals from The Danish Medicine Agency.
The company has been granted (1) approval to import/manufacture/Distribute medical cannabis products, (2) approval to cultivate and product medical cannabis products, (3) approval to handle activities with euphoriant substances – and (4) approval to have STENOCARE medical cannabis oil and capsule products accepted on the Danish Medicine List. The company has cultivated without the use of pesticides in their Danish small scale facility and am in the process of implementing a larger scale indoor state-of-art cultivation facility that build on best practices from greenhouse and clean-room production.
CEO COMMENTS ON PROFITABLE YEAR-END REPORT
Profitable Year-End Report
February 2020
Join the CEO of STENOCARE in his comments on the profitable Year-End Report 2019 and his reflections for the future growth of the company.
STENOCARE is a ”company to watch” for 2020
February, 2020
The new edition of The European Cannabis Report 5th Edition was published February 2020, and in the section “Companies to Watch” the Report profile STENOCARE as one of few medical cannabis leaders in Europe:
Quote from the Report:
“The company is now a leader in the European market; its production and distribution network in Denmark was profitable in 2018 and is currently expanding to Ireland among other emerging markets. This is notable as even large companies have struggled to produce a profit in the early years of the industry”
The European Cannabis Report is a comprehensive source of information covering each European country and its status/progress with medical cannabis. Therefore the Report offer a good insight into market opportunities, key stakeholders and how medical cannabis is applied for treatment of patients in Europe. The European Cannabis Report is free and is published by Prohibition Partners. Access the Report HERE
STENOCARE interview
August 22, 2019
Thomas Skovlund Schnegelsberg, CEO of STENOCARE A/S present the Interim Report Second Quarter 2019 and inform about the current challenges relating to STENOCARE’s Canadian partner, CannTrust. Annabella Pultz from Finwire is hosting the event.
STENOCARE celebrated as the Best IPO 2018 at the ceremony hosted by SvD Börsplus.
May 22, 2019
The STENOCARE Executive Management team, ring the bell at Spotlight Stock Market to start first trade of STENOCARE stocks.
Oct 26, 2018
Listing ceremony , Oct 26, 2018
Listing ceremony of the first medical cannabis company in Europe.
Our strategy to become a leading high-end brand in Europe is fueled by the competitive advantage, that we are operating under very strict regulatory control by the medicines agencies
Mariannne Wier
chairman OF THE BOARD
Financial reports
Dates for release of financial information
January 2020 - June 2020 (Q2)
20/08/2020
Annual General Meeting, Copenhagen 2020
14/05/2020
January 2020 - March 2020 (Q1)
07/05/2020
Year End report 2019
26/02/2020
January 2019 - September 2019 (Q3)
06/11/2019
January 2019 - June 2019 (Q2)
20/08/2019
Annual General Meeting, Copenhagen 2019
16/05/2019
January 2019 - March 2019 (Q1)
07/05/2019
Annual Report 2017-2018
30/04/2019
Year End report 2017-2018
21/02/2019
October 2017 - September 2018 (Q4)
21/11/2018
Executive Management
Thomas Skovlund Schnegelsberg
Schnegelsberg is a co-founder of STENOCARE, born 1965, has extensive experience in management, strategy, business development and brand marketing.
Read more
Rolf Steno
Rolf Steno, born 1965, is a serial entrepreneur and has extensive experience with business innovation, strategy and global sales and marketing. Read more
Søren Kjær
Søren Kjær is a co-founder of STENOCARE, born 1964, has extensive experience with project management, innovation processes and biotechnology from the horticultural industy. Read more
Peter Bugge Johansen
Peter Bugge Johansen, born 1962, State Authorized Public Accountant. Johansen worked 20 years at Interdan Holding A/S the last 6 years as CEO and before that CFO. Read more
Board of Directors
Marianne Wier
Marianne Wier, born 1963, is a Member of the Board since 2018.
Wier holds a law degree from Copenhagen University.
Read more
Søren Melsing Frederiksen
Søren Melsing Frederiksen, born 1976, is a Member of the Board since 2018. Melsing Frederiksen holds a Master of Industrial Drug Development (MIND) from Copenhagen University. Read more
Jeppe Bo Petersen
Jeppe Bo Petersen, born 1966, is a Member of the Board since 2018. Petersen is currently the CEO of Olivia Danmark A/S, which is one of the largest actors within aid and support schemes for patients in their homes. Read more
Rolf Steno
Rolf Steno, born 1965, is a serial entrepreneur and has extensive experience with business innovation, strategy and global sales and marketing. Read more